Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model

Journal of Controlled Release

Volumn 134, Issue 1, 2009, Pages 18-25

  Abu Lila, Amr ^a   Suzuki, Takuya ^a   Doi, Yusuke ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a Institute of Health Biosciences   (Japan)

Author keywords

Anti angiogenic therapy; Anticancer drugs; Cationic liposome; Dorsal air sac (DAS) model; Oxaliplatin

Indexed keywords

ANTI-ANGIOGENIC THERAPY; ANTICANCER DRUGS; CATIONIC LIPOSOME; DORSAL AIR SAC (DAS) MODEL; OXALIPLATIN;

ANIMALS; CELL CULTURE; COMPLEXATION; DRUG THERAPY; ELECTRONIC WARFARE; INTELLIGENT VEHICLE HIGHWAY SYSTEMS; MILITARY ELECTRONIC COUNTERMEASURES; PHOSPHOLIPIDS; PLATINUM; POLYETHYLENE GLYCOLS; SKIN; TUMORS;

LIPOSOMES;

LIPOSOME; OXALIPLATIN; PEGYLATED CATIONIC LIPOSOME; UNCLASSIFIED DRUG;

AIR SAC; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; IMPLANTATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN BLOOD FLOW; TREATMENT OUTCOME;

AIR SACS; ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; CELL LINE, TUMOR; ERYTHROCYTES; LIPOSOMES; MALE; MICE; MODELS, ANIMAL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS;

EID: 59049096095     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.10.018     Document Type: Article

References (41)

1. Nishikawa T., Akiyama N., Kunimasa K., Oikawa T., Ishizuka M., Tsujimoto M., and Natori S. Inhibition of in vivo angiogenesis by N-beta-alanyl-5-S-glutathionyl-3,4 dihydroxyphenylalanine. Eur. J. Pharmacol. 539 (2006) 151-157
2. Masuda T., Ohba S., Kawada M., Osono M., Ikeda D., Esumi H., and Kunimoto S. Antitumor effect of kigamicin D on mouse tumor models. J. Antibiot. (Tokyo) 59 (2006) 209-214
3. Basaki Y., Chikahisa L., Aoyagi K., Miyadera K., Yonekura K., Hashimoto A., Okabe S., Wierzba K., and Yamada Y. Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 4 (2001) 163-173
4. Tashiro T., Kawada Y., Sakurai Y., and Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed. Pharmacother. 43 (1989) 251-260
5. Yonekura K., Basaki Y., Chikahisa L., Okabe S., Hashimoto A., Miyadera K., Wierzba K., and Yamada Y. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin. Cancer Res. 5 (1999) 2185-2191
6. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., Shinohara A., Eriguchi M., Yanagie H., and Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 346 (2008) 143-150
7. Pendyala L., and Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53 (1993) 5970-5976
8. Yu Y., Lou L.G., Liu W.P., Zhu H.J., Ye Q.S., Chen X.Z., Gao W.G., and Hou S.Q. Synthesis and anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate. Eur. J. Med. Chem. (2007)
9. Hofheinz R.D., Gnad-Vogt S.U., Beyer U., and Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16 (2005) 691-707
10. Dudek A.Z., Pawlak W.Z., and Kirstein M.N. Molecular targets in the inhibition of angiogenesis. Expert Opin. Ther. Targets 7 (2003) 527-541
11. Shimizu K., and Oku N. Cancer anti-angiogenic therapy. Biol. Pharm. Bull 27 (2004) 599-605
12. Ye J., Li Y., Hamasaki T., Nakamichi N., Komatsu T., Kashiwagi T., Teruya K., Nishikawa R., Kawahara T., Osada K., Toh K., Abe M., Tian H., Kabayama S., Otsubo K., Morisawa S., Katakura Y., and Shirahata S. Inhibitory effect of electrolyzed reduced water on tumor angiogenesis. Biol. Pharm. Bull. 31 (2008) 19-26
13. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., and McDonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101 (1998) 1401-1413
14. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 (2000) 505-515
15. Pandya N.M., Dhalla N.S., and Santani D.D. Angiogenesis-a new target for future therapy. Vasc. Pharmacol. 44 (2006) 265-274
16. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., and Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J. 18 (1999) 3964-3972
17. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., and Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
18. Staton C.A., Stribbling S.M., Tazzyman S., Hughes R., Brown N.J., and Lewis C.E. Current methods for assaying angiogenesis in vitro and in vivo. Int. J. Exp. Pathol. 85 (2004) 233-248
19. Hussain S., Slevin M., Matou S., Ahmed N., Choudhary M.I., Ranjit R., West D., and Gaffney J. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis 11 (2008) 245-256
20. Kumar R., Yoneda J., Bucana C.D., and Fidler I.J. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int. J. Oncol. 12 (1998) 749-757
21. Shibusa T., Shijubo N., and Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin. Cancer Res. 4 (1998) 1483-1487
22. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9 (2002) 36-44
23. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3 (1992) 65-71
24. Asano M., Yukita A., Matsumoto T., Kondo S., and Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res. 55 (1995) 5296-5301
25. Millauer B., Longhi M.P., Plate K.H., Shawver L.K., Risau W., Ullrich A., and Strawn L.M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56 (1996) 1615-1620
26. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., Torchilin V.P., and Munn L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62 (2002) 6831-6836
27. Strieth S., Eichhorn M.E., Sauer B., Schulze B., Teifel M., Michaelis U., and Dellian M. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer 110 (2004) 117-124
28. Kalra A.V., and Campbell R.B. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting. Pharm. Res. 23 (2006) 2809-2817
29. Nakamura M., Katsuki Y., Shibutani Y., and Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur. J. Pharmacol. 386 (1999) 33-40
30. Oikawa T., Sasaki M., Inose M., Shimamura M., Kuboki H., Hirano S., Kumagai H., Ishizuka M., and Takeuchi T. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res. 17 (1997) 1881-1886
31. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 234 (1959) 469-471
32. Nomura T., Koreeda N., Yamashita F., Takakura Y., and Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm. Res. 15 (1998) 128-132
33. Takeuchi Y., Kurohane K., Ichikawa K., Yonezawa S., Nango M., and Oku N. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer 97 (2003) 2027-2034
34. Allen C., Dos Santos N., Gallagher R., Chiu G.N., Shu Y., Li W.M., Johnstone S.A., Janoff A.S., Mayer L.D., Webb M.S., and Bally M.B. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep. 22 (2002) 225-250
35. Gomer C.J. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem. Photobiol. 54 (1991) 1093-1107
36. Henderson B.W., and Dougherty T.J. How does photodynamic therapy work?. Photochem. Photobiol. 55 (1992) 145-157
37. Jain R.K., Schlenger K., Hockel M., and Yuan F. Quantitative angiogenesis assays: progress and problems. Nat. Med. 3 (1997) 1203-1208
38. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., and Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18 (2000) 2938-2947
39. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., and de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22 (2004) 229-237
40. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol. 30 (2003) 5-13
41. Pietrangeli A., Leandri M., Terzoli E., Jandolo B., and Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur. Neurol. 56 (2006) 13-16